Uveal Melanoma TNM Staging and Survivorship Only to be used where medical device regulations exclude prognostication (including UK, USA and Canada) and MUST NOT be used where such tools are regulated as medical devices (e.g. the European Community)

Version 101.5 Released: 2 July 2021

Date: Patient's Name: Hospital Number: Practitioner's Name: Position:     Age 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 years Epithelioid cells No Yes N/A     Sex Female Male   Closed PAS +ve loops No Yes N/A     Large ultrasound diameter ≤3.0 3.1-6.0 6.1-9.0 9.1-12.0 12.1-15.0 15.1-18.0 >18.0 mm Mitotic rate /40 0-1 2-3 4-7 >7 N/A     Ultrasound thickness ≤3.0 3.1-6.0 6.1-9.0 9.1-12.0 12.1-15.0 > 15.0 mm   Chromosome 3 loss No Yes N/A       Ciliary body involvement No Yes   Regional lymph nodes* No Yes N/A       Extraocular extension No Yes, ≤ 5 Yes, > 5   Distant metastasis* No Yes Yes, ≤3cm Yes, 3.1-8.0 cm Yes, >8.0 cm N/A                   Years since treatment 0-1 1-2 2-3 3-4 4-5 5-6 6-7 7-8 years   First scan 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 years           Time from Metastasis to death 6 7 8 9 10 11 12 months           Number needed to scan N/A 20 10 5 4 2         Melanoma Patients General Population * Parameters indicated by an asterisk are included for TNM staging only and have no effect on the survival curve T: ... N: ... M: ... Stage: ... Threshold for next scan at: ... Survival: Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10 Controls: ... ... ... ... ... ... ... ... ... ... Subjects: ... ... ... ... ... ... ... ... ... ... Difference: ... ... ... ... ... ... ... ... ... ... Relative: ... ... ... ... ... ... ... ... ... ...   Dept. of Medical Physics & Clinical Engineering, Royal Liverpool University Hospital

Only to be used where medical device regulations exclude prognostication (including UK, USA and Canada) and MUST NOT be used where such tools are regulated as medical devices (e.g. the European Community)

Reference: A. Eleuteri, B.E. Damato, S.E. Coupland, A.F.G. Taktak (2012). Enhancing survival prognostication in patients with choroidal melanoma by integrating pathologic, clinical and genetic predictors of metastasis. Int J Biomedical Eng and Tech, 8, 1, 18 - 35 (Link)  

Home | Terms and Conditions |Privacy | Background | Links | Contact us